Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Barr expecting

This article was originally published in The Tan Sheet

Executive Summary

CEO Bruce Downey believes Barr has "met the standard the FDA laid out for us in the letter denying our [Plan B switch] application a few months ago," the exec said Feb. 2, explaining the firm's expectation of receiving an "approvable letter" from the agency. "We followed the recommendation, we followed the pathway that was sort of suggested in that letter, I think we have done it...professionally, done it appropriately and we have met all reasonable objections." FDA failed to act on the application by the PDUFA deadline of Jan. 21 (1"The Tan Sheet" Jan. 24, 2005, p. 6)...

You may also be interested in...



No Plan B Switch Parade As User Fee Deadline Comes And Goes

FDA will deliver a decision in the "near future" on whether the Plan B emergency contraceptive pill is "approvable" for over-the-counter use in women age 16 and up, according to manufacturer Barr Labs

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel